Searchable abstracts of presentations at key conferences in endocrinology

ea0015oc24 | Tumours, diabetes, bone | SFEBES2008

The calcilytic agent NPS2143 rectifies hypocalcaemia in a mouse model, Nuf, that is due to an activating calcium-sensing-receptor (CaSR) mutation: relevance to autosomal dominant hypocalcaemia with hypercalciuria

Hannan Fadil , Walls Gerard , Kallay Eniko , Nesbit M Andrew , Hough Tertius , Cox Roger , Hu Jianxin , Spiegel Allen , Thakker Rajesh

The G-protein coupled calcium-sensing-receptor (CaSR) regulates calcium homeostasis and inactivating mutations result in familial hypocalciuric hypercalcaemia (FHH), whilst activating mutations result in autosomal dominant hypocalcaemia with hypercalciuria (ADHH). Allosteric CaSR modulators consist of: calcimimetics, which activate the CaSR e.g. Cinacalcet, that is used to treat the hypercalcaemia of chronic renal failure and metastatic parathyroid carcinoma; and calcilytics e...

ea0038p186 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015

Studies of Nuf mice with an activating calcium-sensing receptor (CaSR) mutation demonstrate the CaSR to regulate pancreatic beta-cell mass and glucose homeostasis

Babinsky Valerie N , Hannan Fadil M , Nesbit M Andrew , Hough Alison , Stewart Michelle , Joynson Elizabeth , Hough Tertius A , Bentley Liz , Aggarwal Abhishek , Kallay Eniko , Wells Sara , Cox Roger D , Richards Duncan , Thakker Rajesh V

The modulation of pancreatic islet mass represents a novel therapeutic approach for the management of diabetes mellitus. G-protein coupled receptors (GPCRs) regulate beta-cell expansion and proliferation, and the objective of this study was to assess whether the calcium-sensing receptor (CaSR), which is an abundantly expressed beta-cell GPCR, may influence islet mass and systemic glucose homeostasis, and thus represent an exploitable drug target in some forms of diabetes. We c...